Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tianyang Xi

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentFred Kim, Tianyang Xi, Han Joo Lee, et al.
Biochemical and Biophysical Research Communications|October 19, 2017
MicroRNA-126-3p attenuates blood-brain barrier disruption, cerebral edema and neuronal injury following intracerebral hemorrhage by regulating PIK3R2 and AktTianyang Xi, Feng Jin, Ying Zhu, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 11, 2024
Therapeutic effects of mirodenafil, a phosphodiesterase 5 inhibitor, on stroke models in ratsFred Kim, Padmanabh Singh, Hyunji Jo, et al.
The Journal of Biological Chemistry|October 20, 2018
miR-27a-3p protects against blood-brain barrier disruption and brain injury after intracerebral hemorrhage by targeting endothelial aquaporin-11Tianyang Xi, Feng Jin, Ying Zhu, et al.
The Journal of Prevention of Alzheimer'S Disease|September 5, 2025
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's diseaseDavid Greeley, Marshall Nash, Brad Herskowitz, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentFred Kim, Tianyang Xi, Han Joo Lee, et al.
Biochemical and Biophysical Research Communications|October 19, 2017
MicroRNA-126-3p attenuates blood-brain barrier disruption, cerebral edema and neuronal injury following intracerebral hemorrhage by regulating PIK3R2 and AktTianyang Xi, Feng Jin, Ying Zhu, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 11, 2024
Therapeutic effects of mirodenafil, a phosphodiesterase 5 inhibitor, on stroke models in ratsFred Kim, Padmanabh Singh, Hyunji Jo, et al.
The Journal of Biological Chemistry|October 20, 2018
miR-27a-3p protects against blood-brain barrier disruption and brain injury after intracerebral hemorrhage by targeting endothelial aquaporin-11Tianyang Xi, Feng Jin, Ying Zhu, et al.
The Journal of Prevention of Alzheimer'S Disease|September 5, 2025
A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's diseaseDavid Greeley, Marshall Nash, Brad Herskowitz, et al.
Pageof 1